An observational study in Breast Cancer, Metastatic Breast Cancer and Triple Negative Breast Cancer, sponsored by Royal Marsden NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by Royal Marsden NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Triple Negative Breast Neoplasms with a site in United Kingdom — 24 open to participants now, 42 under way, 10 of them phase 3. Triple Negative Breast Neoplasms · United Kingdom.
Among the 94 studies in Triple Negative Breast Neoplasms with a site in United Kingdom, this one is one of 2 that started in 2026, is one of 6 observational ones, reaches primary completion later than 41 of the 41 other live ones, and was the 93rd registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →24 of the 94 studies in Triple Negative Breast Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:
Queen Mary University of London · Sites in United Kingdom
Ages 18+ · Women only
Bristol-Myers Squibb · Sites in United Kingdom, United States, Argentina and 25 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in United Kingdom, United States, Argentina and 38 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in United Kingdom, United States, Argentina and 32 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United Kingdom, United States, Australia and 7 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 47 · Phase 2 41 · Phase 3 22
First in 2012; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 193 across 106 observational studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 187 across the 88 interventional studies, 200 across the 6 observational. Of the 49 that completed or were terminated, 28 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 94 have an industry lead sponsor. The 10 most frequent:
Royal Marsden NHS Foundation Trust is the lead sponsor of 275 studies on the registry; 54 are open to participants now.
Royal Marsden NHS Foundation Trust has 4 studies filed under Triple Negative Breast Neoplasms — fewer than ten, so there is no comparison to draw.
13 of the studies in Triple Negative Breast Neoplasms with a site in United Kingdom that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05382286Phase 3Gilead SciencesStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | 2027-02 |
| NCT05633654Phase 3Gilead SciencesStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | 2027-06 |
| NCT06545331ExelixisStudy of XB010 in Subjects With Solid Tumors | 2026-11-23 |
| NCT05082259Institute of Cancer Research, United KingdomASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab | 2026-12 |
| NCT03740893Institute of Cancer Research, United KingdomPHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer | 2026-12 |
Add all 13 to your calendar (.ics) → With an account.
Among the 94 studies in Triple Negative Breast Neoplasms with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
FORTITUDE is a translational research study that aims to collect serial multi-site needle biopsy samples of tumour tissue and blood from metastatic breast cancer patients. Cancer biopsies are generally performed when cancer is diagnosed and are sometimes repeated when the cancer is suspected to have spread but this is not mandatory. However, studies have shown that cancers change with time and evolve to become resistant to therapy. The purpose of this study is to assess the feasibility of biopsies of multiple cancer sites across different time points during treatment and understand how cancers evolve and change throughout treatment. The findings of this study could pave the way for using cancer biopsies more frequently in the clinic to pick up changes in cancer behaviour that could influence treatment choice. The samples collected from this study will be used for molecular and genetic research to increase our understanding of how metastatic breast cancer changes during treatment and will enable us to develop new cancer treatments and new ways of monitoring response to cancer therapies.
Breast cancer is the most frequently diagnosed cancer in women and is the second leading cause of female cancer death in the UK. Metastatic breast cancer has a historical five-year survival of 26% in England, although there is considerable variation by histology, with the poorest outcomes observed in patients with triple negative breast cancer (TNBC). Therapeutic approaches are chosen based on tumour clinical and pathological features, including oestrogen hormone receptor (ER) and human epidermal growth factor receptor 2 (HER2) status, however, patients with advanced disease almost inevitably develop therapy resistance and disease progression.
Next generation sequencing technologies have allowed us to understand the biology of breast cancer at a previously unprecedented depth. While the molecular landscape of early breast cancer has been extensively investigated, our understanding of the molecular basis of metastatic breast cancer remains more limited. In the clinic, metastatic breast cancer tissue is often biopsied once, from a single site, at the time of diagnosis. This biopsy sampling method is under-representative of the total disease burden and does not take into consideration the fact that metastatic disease is heterogeneous and evolves during the course of the disease.
The development of a method to serially sample multiple disease sites that is acceptable to patients will allow comprehensive evaluation of the heterogeneity of their disease and allow a deeper understanding of tumour heterogeneity, the mechanisms underlying treatment resistance as well as the biological processes governing metastatic behaviour. This will enable us to develop new cancer treatments and new ways of monitoring response to cancer therapies.
FORTITUDE will evaluate established standard of care biopsy techniques (fine needle biopsy and core needle biopsy) in a serial and multisite approach in patients with metastatic breast cancer or with locally advanced but inoperable breast cancer. Tumour tissue will be acquired at:
Baseline (mandatory), defined as:
No more than a total of four lesions will be biopsied in one sitting, with a maximum of three anatomical sites targeted (and no more than two solid organs). When tissue sampling is required as part of clinical care, patients will be invited to undergo additional serial multisite sampling. The sampling scheme will be repeated at subsequent relevant time points. This will be coupled with blood sampling when clinically indicated, including prior to each cycle of systemic therapy, and on disease progression. Furthermore, any cerebrospinal, ascitic and pleural fluid drained as part of clinical care can also be collected and profiled within this study.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.
This study's planned enrollment of 200 is close to the median of 193 across 106 observational studies indexed under Triple Negative Breast Neoplasms.
Browse Triple Negative Breast Neoplasms studies →Royal Marsden NHS Foundation Trust is the lead sponsor of 275 studies on the registry; 54 are open to participants now.
Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Metastatic breast cancer or locally advanced, inoperable breast cancer patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Proportion of patients having two or more tumour sites sampled in one procedural sitting when technically feasible
Time frame: Through study completion, 15 years
Proportion of patients having longitudinal sampling in those progressing on treatment
Time frame: Through study completion, 15 years
Proportion of patients willing to undergo multisite sampling again in the future if clinically required
Time frame: Through study completion, 15 years
Quantification of procedural complication rates
Time frame: Through study completion, 15 years
Quantification of duration of biopsy procedures
Time frame: Through study completion, 15 years
Accuracy of tumour biopsies
Accuracy may be defined as the successful identification of tumour tissue through biopsy, as confirmed by histopathology examination, or by other exploratory means such as using CT images to measure actual needle tip position compared to planning scans
Time frame: Through study completion, 15 years
Quantification of proportion of samples adequate for molecular profiling
Time frame: Through study completion, 15 years
Number of clinically relevant molecular alterations detected using multisite, multiregion, and serial sampling
This outcome will assess whether the use of multisite (different anatomical locations), multiregion (multiple regions within a single tumor), and serial (longitudinal, across time points) sampling strategies increases the detection of clinically relevant molecular alterations, compared to standard single-site or single-timepoint sampling.
Time frame: Through study completion, 15 years
Characterisation of change in molecular phenotypes and genotypes between different regions in a single tumour
Time frame: Through study completion, 15 years
Characterisation of change in molecular phenotypes and genotypes between different tumours across time
Time frame: Through study completion, 15 years
Concordance and comparison of molecular alterations between liquid biopsies (blood, ascites, pleural fluid) and tumour needle biopsy samples
Time frame: Through study completion, 15 years
Characterisation of molecular and imaging tumour profiles and correlation with clinical characteristics, treatment responses and patient outcomes
Time frame: Through study completion, 15 years
Started Feb 2026 (actual). Primary completion is estimated for Apr 2040, 170 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Triple Negative Breast Neoplasms →
Royal Marsden NHS Foundation Trust →